Zacks Research Lifts Earnings Estimates for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Analysts at Zacks Research increased their Q3 2027 EPS estimates for shares of Avanos Medical in a research report issued on Tuesday, May 26th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.26 for the quarter, up from their previous forecast of $0.25. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Avanos Medical’s current full-year earnings is $1.06 per share. Zacks Research also issued estimates for Avanos Medical’s FY2027 earnings at $0.94 EPS.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, topping the consensus estimate of $0.16 by $0.06. The company had revenue of $182.20 million for the quarter, compared to the consensus estimate of $170.00 million. Avanos Medical had a negative net margin of 10.39% and a positive return on equity of 5.39%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 EPS.

Several other research analysts have also recently issued reports on the stock. Weiss Ratings upgraded shares of Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Wall Street Zen cut shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Two analysts have rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

Avanos Medical Stock Up 0.2%

Shares of Avanos Medical stock opened at $24.80 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40. Avanos Medical has a 1 year low of $9.30 and a 1 year high of $24.91. The firm’s 50-day moving average is $20.33 and its two-hundred day moving average is $15.33. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -15.40 and a beta of 1.58.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. grew its holdings in Avanos Medical by 1,596,514.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 14,896,413 shares of the company’s stock worth $167,287,000 after acquiring an additional 14,895,480 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of Avanos Medical by 28.0% in the 4th quarter. Armistice Capital LLC now owns 3,200,000 shares of the company’s stock valued at $35,936,000 after buying an additional 700,000 shares in the last quarter. State Street Corp boosted its holdings in shares of Avanos Medical by 2.8% in the 4th quarter. State Street Corp now owns 1,954,785 shares of the company’s stock valued at $21,952,000 after buying an additional 53,523 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Avanos Medical by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,084,504 shares of the company’s stock valued at $12,180,000 after buying an additional 16,980 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Avanos Medical by 20.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,040,666 shares of the company’s stock valued at $11,687,000 after buying an additional 176,716 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors.

About Avanos Medical

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.